logo
enCore Energy Receives Radioactive Materials License for Upper Spring Creek ISR Uranium Project, South Texas; Commences Construction

enCore Energy Receives Radioactive Materials License for Upper Spring Creek ISR Uranium Project, South Texas; Commences Construction

Cision Canada29-05-2025

DALLAS, May 29, 2025 /CNW/ - enCore Energy Corp. (NASDAQ:EU| TSXV: EU) (the "Company" or "enCore"), America's Clean Energy Company TM, today announced the approval for the inclusion of the Upper Spring Creek In-Situ Recovery ("ISR") Uranium Project (the "Project") in the existing Radioactive Materials License ("RML") from the TCEQ (Texas Commission on Environmental Quality). This license allows enCore to handle radioactive materials, which includes the final product, U 3 O 8 ("uranium"). The current RML includes the Rosita Uranium Project, which has now been extended to cover the Upper Spring Creek Project's Brown Area. The RML allows the construction of wellfields and a Satellite Ion Exchange ("IX") Plant to commence, which will feed the Rosita ISR Uranium Central Processing Plant ("CPP"). These Satellite IX Plants, located adjacent to wellfields, are a key part of the satellite ISR process; they are modular, efficient, and relocatable, allowing for cost-effective uranium extraction across multiple remote sites which can be moved once a wellfield is depleted. The RML is scheduled for renewal in 2032, provided the Project's operation remains in compliance. The RML provides safety, material handling, record keeping and reporting protocols.
William M. Sheriff, Executive Chairman of enCore Energy stated: "The receipt of the RML, allowing enCore to build its next remote Satellite Ion Exchange Plant and wellfield in a timely manner from application, is a testament to the efficiency of the Texas Commission on Environmental Quality. The ability to operate and issue these critical permits under authority of being an Agreement State in conjunction with the U.S. Nuclear Regulatory Commission is a clear competitive advantage for enCore. This is our third permitted facility in Texas with each of our preceding permits having been granted in 20 months or less. The Upper Spring Creek Project brings important uranium mineralization into the operations of the Company, and we look forward to recovering (capturing) increasing amounts of uranium from late this year into 2026. On behalf of the Board, I want to thank our dedicated team for bringing this project to the point of permit application and issuance. We have the utmost confidence in them completing the new construction in the coming months."
enCore has commenced advancement of the Project with drill rigs moving to site to begin development of the production wellfield; enCore previously began staging equipment in anticipation of receiving this approval. Construction activities will include surface preparation, well construction, road construction and installation of support facilities and utilities. The construction of the Satellite IX Plant concrete pad is planned to start in 30 days.
enCore now holds two RML's in Texas; one for the Alta Mesa ISR Uranium Project and the amended RML which now includes the Upper Spring Creek's Brown Area, Rosita and Kingsville Project areas. The TCEQ is a part of the United States Nuclear Regulatory Commission's ("NRC") Agreement State Program where Texas assumes regulatory authority over certain radioactive materials, including production of uranium. As part of the agreement, regulations adopted by Texas are required to be compatible with NRC regulations.
About the Upper Spring Creek ISR Uranium Project
The 100% Company-owned Project is a planned Satellite IX Plant operation for the Rosita CPP. The Project consists of several future potential production units within the historic Clay West uranium district. The Project was previously held by Signal Equities LLC, who previously licensed and permitted the property as an ISR uranium project, maintaining the aquifer exemption and ceased work following continued low uranium spot prices. In December 2020, the Company acquired the Project. The uranium mineralized sands that are associated with the project area lie within the Oakville Formation. These historic uranium producing sands stretch across an area of approximately 120 miles long by approximately 20 miles wide in South Texas. The uranium mineralized ore body at the Upper Spring Creek Project occurs at depths typically between 300 and 450 feet from surface.
Rosita ISR Uranium Central Processing Plant
The Rosita CPP can receive uranium-loaded resin from remote project areas across the South Texas region through a network of Satellite IX Plants. These Satellite IX Plants, located near wellfields, are a key component of the ISR uranium extraction process. A lixiviant, consisting of groundwater mixed with oxygen and sodium bicarbonate, is injected into the wellfield using ISR technology, where it dissolves uranium from the underground sandstone. The uranium-bearing solution is then pumped to the surface and directed through the IX columns at the nearby Satellite IX Plant, where uranium is absorbed onto resin beads. The uranium-loaded resin is then transported to the Rosita CPP, where the uranium is removed from the resin and processed into yellowcake. Once processed, the resin is recycled and trucked back to the Satellite IX Plants for reuse. These modular, efficient, and relocatable IX Plants allow for cost-effective operation across multiple sites without the need to construct full processing facilities at each location, and they can be relocated once a wellfield is depleted.
Technical Disclosure and Qualified Person
John M. Seeley, Ph.D., P.G., C.P.G., enCore's Chief Geologist, and a Qualified Person under Canadian National Instrument 43-101 and United States Securities and Exchange Commission (SEC) S-K 1300, has reviewed and approved the technical disclosure in this news release on behalf of the Company.
About enCore Energy Corp.
enCore Energy Corp., America's Clean Energy Company™, is committed to providing clean, reliable, and affordable fuel for nuclear energy as the only United States uranium company with multiple central processing plants in operation. enCore operates the 100% owned and operated Rosita CPP in South Texas and the 70/30 joint venture Alta Mesa CPP with Boss Energy Ltd., with enCore operating as the project manager.
The enCore team is led by industry experts with extensive knowledge and experience in all aspects of ISR uranium operations and the nuclear fuel cycle. enCore solely utilizes ISR for uranium extraction, a well-known and proven technology co-developed by the leaders at enCore Energy. Following upon enCore's demonstrated success in South Texas, future projects in enCore's planned project pipeline include the Dewey-Burdock project in South Dakota and the Gas Hills project in Wyoming. The Company holds other assets including non-core assets and proprietary databases. enCore is committed to working with local communities and indigenous governments to create positive impact from corporate developments.
Cautionary Note Regarding Forward Looking Statements:
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and Canadian securities laws that are based on management's current expectations, assumptions, and beliefs. Forward-looking statements can often be identified by such words as "expects", "plans", "believes", "intends", "continue", "potential", "remains", and similar expressions or variations (including negative variations) of such words and phrases, or statements that certain actions, events or results "may", "could", or "will" be taken.
Forward-looking statements and information that are not statements of historical fact include, but are not limited to, any information relating to statements regarding future or potential extraction, and any other statements regarding future expectations, beliefs, goals or prospects, statements regarding the success of current and future ISR operations, including projects in our pipeline, our development plans including construction of wellfields and a satellite IX plant to feed the Rosita Project, the commencement of and timing of commencement of construction at the Project, our future extraction plans and our commitment to working with local communities and indigenous governments to create positive impact from corporate developments should be considered forward looking statements. All such forward-looking statements are not guarantees of future results and forward-looking statements are subject to important risks and uncertainties, many of which are beyond the Company's ability to control or predict, that could cause actual results to differ materially from those expressed in any forward looking statement, including those described in greater detail in our filings with the SEC and on SEDAR+, particularly those described in our Annual Report on Form 10-K, annual information from and MD&A. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with assumptions regarding project economics; discount rates; expenditures and the current cost environment; timing and schedule of the projects, general economic conditions; adverse industry events; future legislative and regulatory developments; the ability of enCore to implement its business strategies; and other risks. A number of important factors could cause actual results or events to differ materially from those indicated or implied by such forward-looking statements, including without limitation exploration and development risks, changes in commodity prices, access to skilled personnel, the results of exploration and development activities; extraction risks; uninsured risks; regulatory risks; defects in title; the availability of materials and equipment, timeliness of government approvals and unanticipated environmental impacts on operations; litigation risks; risks posed by the economic and political environments in which the Company operates and intends to operate; increased competition; assumptions regarding market trends and the expected demand and desires for the Company's products and proposed products; reliance on industry equipment manufacturers, suppliers and others; the failure to adequately protect intellectual property; the failure to adequately manage future growth; adverse market conditions, the failure to satisfy ongoing regulatory requirements and factors relating to forward looking statements listed above. Should one or more of these risks materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated, or expected. The Company assumes no obligation to update the information in this communication, except as required by law. Additional information identifying risks and uncertainties is contained in filings by the Company with the various securities commissions which are available online at www.sec.gov and www.sedarplus.ca. Forward-looking statements are provided for the purpose of providing information about the current expectations, beliefs and plans of management. Such statements may not be appropriate for other purposes and readers should not place undue reliance on these forward-looking statements, that speak only as of the date hereof, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

AstraZeneca signals intent to join Inka Health's AI-driven oncology consortium
AstraZeneca signals intent to join Inka Health's AI-driven oncology consortium

The Market Online

time33 minutes ago

  • The Market Online

AstraZeneca signals intent to join Inka Health's AI-driven oncology consortium

Onco-Innovations' (CBOE CA:ONCO) wholly-owned subsidiary, Inka Health Corp., has received a formal Expression of Interest (EOI) from AstraZeneca (NASDAQ:AZN) to participate as a founding member in the Predictive Oncology Outcomes using Multimodal AI (PROmAI) Consortium The PROmAI Consortium, spearheaded by Inka Health, wants to advance AI methodologies to improve predictive modeling in oncology AstraZeneca's EOI could mark a significant step toward establishing a multi-stakeholder platform focused on enhancing the reliability, interpretability, and regulatory alignment of AI-driven insights in cancer research Onco-Innovations (CBOE CA:ONCO) last traded at C$2.23 This content has been prepared in collaboration with Onco-Innovations Ltd . , a third-party issuer, and is intended for informational purposes only. Onco-Innovations' (CBOE CA:ONCO) wholly-owned subsidiary, Inka Health Corp., has received a formal Expression of Interest (EOI) from AstraZeneca (NASDAQ:AZN) to participate as a founding member in the Predictive Oncology Outcomes using Multimodal AI (PROmAI) Consortium. The PROmAI Consortium, spearheaded by Inka Health, wants to advance AI methodologies to improve predictive modeling in oncology. The initiative seeks to address challenges in translational modeling, particularly during the transition from early- to late-stage clinical development, by integrating insights from pharmaceutical, data science, and clinical research sectors. AstraZeneca's EOI could mark a significant step toward establishing a multi-stakeholder platform focused on enhancing the reliability, interpretability, and regulatory alignment of AI-driven insights in cancer research. The company's involvement in the exploratory phase will include joint planning, early input into project direction, and strategic alignment on key use cases. Inka Health is still ready to mingle with other global pharmaceutical companies regarding participation in the Consortium and plans to provide further updates as these discussions progress. The PROmAI initiative will leverage a wide range of multimodal data—including molecular, clinical, and imaging datasets—combined with emerging techniques in causal AI. The goal is to foster innovation in predictive oncology, improve transparency in AI applications, and support frameworks that align with both regulatory and payer expectations. For Inka Health, the Consortium represents a strategic opportunity to lead the development of next-generation AI tools in oncology. The company's proprietary platform, SynoGraph, utilizes causal inference to identify patient subgroups most likely to respond to specific treatments, thereby supporting precision medicine and optimizing clinical trial design. Onco-Innovations views AstraZeneca's interest as a strong endorsement of the Consortium's potential to shape the future of oncology research and drug development. 'This is not just about proving that AI can work in oncology-it's about shaping how it should work in ways that matter to regulators, clinicians, and ultimately patients. Having AstraZeneca engage at this early stage signals a shared commitment to advancing practical, credible AI applications in one of medicine's most complex domains,' Paul Arora, CEO of Inka Health, said in a news release. 'As leaders in this space, we see PROmAI not only as a research initiative but as a foundation for setting standards around trust, utility, and translational impact in oncology-focused AI.' Onco-Innovations Ltd. studies cancer research and treatment, specializing in oncology. Onco-Innovations (CBOE CA:ONCO) closed 12.06 per cent higher on Friday at C$2.23. Join the discussion: Find out what everybody's saying about this stock on the Onco-Innovations Bullboard, and check out the rest of Stockhouse's stock forums and message boards. Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein.

My 3 Favorite Ultra-High-Yield Dividend Stocks to Buy Now
My 3 Favorite Ultra-High-Yield Dividend Stocks to Buy Now

Globe and Mail

time37 minutes ago

  • Globe and Mail

My 3 Favorite Ultra-High-Yield Dividend Stocks to Buy Now

I'm not getting any younger. These days, I'm thinking more and more about retiring and the stream of passive income that will allow me to thrive instead of merely surviving. I'm attracted to high yields like everybody else, but there are more important factors to consider. Ares Capital (NASDAQ: ARCC), W.P. Carey (NYSE: WPC), and Realty Income (NYSE: O) have been hovering at the top of my list of dividend stocks to buy because they do more than just offer a high yield. All three of these stocks have remarkable track records when it comes to maintaining and raising their payouts. At the moment, they offer yields that are more than triple the average yield you'd receive from the average dividend payer in the S&P 500 index. Put it together, and they're hard to ignore. 1. Ares Capital Ares Capital is the largest business development company (BDC) with shares that trade publicly. These specialized entities fill in the private lending gap created by American banks that no longer lend directly to midsize businesses. Starved for capital, midsize businesses are willing to borrow at very attractive interest rates. The weighted average yield on Ares Capital's $27 billion portfolio was 9.8% at the end of March. Ares Capital isn't shy about sharing its investment income with shareholders. Just about every penny earned is paid out to a quarterly dividend that offers an 8.7% yield at recent prices. The BDC has a tendency to make extra dividend payments in times of plenty rather than commit to a permanent payout increase. Investors seeking a reliable income base will be glad to know its quarterly payout has been rising, or at least stable, since 2009. Direct lending to midsize businesses can be risky, but Ares Capital's enormous footprint in the asset management space means it has plenty of excellent borrowers to choose from. The BDC is externally managed by a subsidiary of Ares Management, a leading global alternative investment manager with around $546 billion in assets under management. Members of Ares Capital's underwriting team have over 25 years of experience on average, and it shows. At the end of March, just 0.9% of Ares Capital's total investment portfolio was on nonaccrual status. 2. W.P. Carey If you're willing to accept a smaller yield upfront in exchange for frequent payout increases, consider W.P. Carey. Shares of this diversified real estate investment trust (REIT) have been under pressure since it spun off its office building portfolio in 2023 and lowered its dividend accordingly. Throughout the Great Recession, W.P. Carey managed to raise its quarterly payout. The COVID-19 pandemic pulled the rug out from under its office portfolio, but it only lowered its payout by 19.7% in 2023, plus shareholders received new shares of Net Lease Office Properties. W.P. Carey has raised its dividend every quarter since it spun off Net Lease Office Properties. At recent prices, it offers a huge 5.7% yield that investors can reasonably expect to grow significantly in the years ahead. Its portfolio is highly diversified. It's three largest tenants combined are responsible for just 7% of total rent payments received annually. In April, management told us to expect between $4.82 and $4.92 in adjusted funds from operations (FFO), a proxy for earnings used to evaluate REITs. That's more than enough to meet a dividend commitment currently set at an annualized $3.60 and raise it further. 3. Realty Income Like W.P. Carey, Realty Income is a diversified REIT with steadily growing profits produced by a large portfolio of commercial property. Its cash flows grow reliably because annual rent escalators are written into long-term net leases that transfer all the variable expenses associated with building ownership to the tenant. At recent prices, Realty Income shares offer a 5.7% yield and confidence that comes with a very long payout raising streak. The company recently raised its monthly dividend payout for the 131st time since going public in 1994. With a 56-year operating history and 15,627 commercial properties spread throughout eight countries, Realty Income can borrow at interest rates that its smaller peers can only dream about. The company recently sold around $1.5 billion worth of euro-denominated notes at an effective rate of just 3.7%. For many companies that own their facilities, selling their buildings to Realty Income and leasing them back is an increasingly popular financing option. With the vast majority of leaseable buildings still owned by the businesses that operate in them, investors can look forward to many more years of steady payout raises. Should you invest $1,000 in Ares Capital right now? Before you buy stock in Ares Capital, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Ares Capital wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!* Now, it's worth noting Stock Advisor 's total average return is1,062% — a market-crushing outperformance compared to177%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 23, 2025

2 Stocks That Have Doubled This Year and Are Still Worth Buying
2 Stocks That Have Doubled This Year and Are Still Worth Buying

Globe and Mail

timean hour ago

  • Globe and Mail

2 Stocks That Have Doubled This Year and Are Still Worth Buying

Positive, company-specific developments have led to shares of TransMedics Group (NASDAQ: TMDX) and FuboTV (NYSE: FUBO) more than doubling this year, even as the S&P 500 is barely in the green since January. Investing wisdom advises us to buy low, and some might think that after a greater than 100% return in six months, it's too late to get in on these stocks. However, TransMedics Group and FuboTV still have excellent prospects that could lead to better-than-average returns over the long run. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » 1. TransMedics Group TransMedics Group, a medical device specialist that developed an innovative method for storing organs for transplant, entered the year facing challenges. First, the company's guidance disappointed investors. Second, TransMedics was the subject of a short-seller report from Scorpion Capital, which made a series of serious allegations, including claims that TransMedics Group is engaged in organ trafficking. However, the company has performed well this year because of better-than-expected financial results. In the first quarter, TransMedics' revenue increased by 48% year over year to $143.5 million. The company's net earnings per share came in at $0.70, doubling compared to the year-ago period. To top it all off, TransMedics raised its guidance for the full fiscal year 2025. With results like these, even the short-seller report that sank its stock price now looks like a distant memory. The best part is that there is still considerable upside potential for TransMedics Group. The company's organ care system (OCS) technology aims to mimic the physiology of the human body, enabling the storage of organs for longer periods, which results in significantly higher usage rates compared to traditional cold storage methods. It's already hard enough to find available transplants. It's a shame if they go to waste due to poor storage. Thus, TransMedics Group is helping revolutionize the organ donation business thanks to its OCS, and there is plenty of room for growth. The company estimates organ donations will grow at a decent rate through the next few years, at least. Capturing a larger share of the market and improving utilization rates for existing organ donations -- even if there aren't more donors over time -- should lead to stronger financial results for TransMedics Group. That's why the stock remains a buy today, at least for investors willing to stay the course for a while, even after doubling in value already this year. 2. FuboTV In January, streaming specialist FuboTV announced it was merging with Disney 's Hulu+ Live TV. The deal makes FuboTV far more attractive than it was before for several reasons. First, it helps diversify the company's offerings. FuboTV was known for its laser focus on sports streaming, a niche of the market that can be somewhat seasonal. Second, the deal came with the cancellation of the Venu initiative. Disney, Fox, and Warner Bros. Discovery were planning to launch a competing sports-focused streaming platform called Venu, which might have killed FuboTV altogether, considering the company's subscription growth rate had plummeted. Third, FuboTV got a nice infusion of cash as part of the deal. It got $220 million from the former backers of Venu. And that's on top of a $145 million term loan from Disney. Last but not least, Disney is now FuboTV's majority shareholder. The backing of a longtime successful media giant with equally successful ventures in the streaming niche will be of massive help to FuboTV. Yes, the stock has already skyrocketed this year, but considering the long-term opportunity in streaming, there should still be plenty of upside for FuboTV. Streaming accounted for 44.8% of television viewing time in May in the U.S., surpassing the combined share of broadcast and cable for the first time. Even so, that's in the U.S., one of the more penetrated markets. And even here, streaming likely hasn't peaked. That points to a massive whitespace worldwide. FuboTV will have to deal with stiff competition, but the company's new standing after the merger with Hulu+ Live TV -- and the backing of Disney -- should work wonders over the long run. That's why the stock is still a buy. Should you invest $1,000 in TransMedics Group right now? Before you buy stock in TransMedics Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and TransMedics Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!* Now, it's worth noting Stock Advisor 's total average return is1,062% — a market-crushing outperformance compared to177%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 23, 2025

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store